Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.12 USD | +1.75% | -11.73% | -51.71% |
05-10 | UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating | MT |
05-10 | Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.71% | 2.5B | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.39% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Transcript : ACADIA Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 08, 2021